

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

SUP-T1

RRID:CVCL_1714

Type: Cell Line

Proper Citation

RRID:CVCL_1714

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1714

Proper Citation: RRID:CVCL_1714

Description: Cell line SUP-T1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Childhood T lymphoblastic lymphoma

Defining Citation: [PMID:3004618](#), [PMID:3010463](#), [PMID:3036367](#), [PMID:3107838](#), [PMID:3935328](#), [PMID:6437672](#), [PMID:6438800](#), [PMID:7849311](#), [PMID:8558920](#), [PMID:9933131](#), [PMID:11264379](#), [PMID:17170727](#), [PMID:20164919](#), [PMID:22292511](#), [PMID:22460905](#), [PMID:22675565](#), [PMID:25355872](#), [PMID:27397505](#), [PMID:29304865](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32938764](#), [PMID:35839778](#)

Comments: Virology: Susceptible to infection by herpesvirus 6B (HHV-6B) strain Z29 (PubMed=29304865)., Virology: Useful for studies of cell fusion and cytopathic effects of HIV-1 as well as cytopathic isolates of HIV-2., Characteristics: Has chromosomal translocations involving the genes for the alpha and beta subunits of TCR thus preventing surface expression of the endogenous TCR complex., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SUP-T1

Synonyms: Sup-T1, SUPT-1, SupT-1, Sup T-1, SUP T-1, SUP T1, Sup T1, SupT1, SUPT1, Tsup-1, VB, Stanford University Pediatric T-cell line 1

Cross References: BTO:BTO_0003582, CLO:CLO_0009164, EFO:EFO_0022582, CLDB:cl4420, CLDB:cl4421, CLDB:cl4422, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1942, BCRC:60191, BEI_Resources:ARP-100, BEI_Resources:ARP-150, BioGRID_ORCS_Cell_line:456, BioSample:SAMN03471266, BioSample:SAMN03473416, BioSample:SAMN10987655, cancercellines:CVCL_1714, Cell_Model_Passport:SIDM01154, ChEMBL-Cells:ChEMBL3308368, ChEMBL-Targets:ChEMBL614940, Cosmic:687855, Cosmic:909743, Cosmic:1086322, Cosmic:1281384, Cosmic:1330493, Cosmic:1524822, Cosmic:1664528, Cosmic:1760532, Cosmic:2165716, Cosmic:2602931, Cosmic-CLP:909743, DepMap:ACH-000953, DSMZ:ACC-140, DSMZCellDive:ACC-140, ECACC:95013123, EGA:EGAS00001000978, GDSC:909743, GEO:GSM482493, GEO:GSM887662, GEO:GSM888754, GEO:GSM1670494, ICLC:HTL96007, LiGeA:CCLE_331, LINCS_LDP:LCL-1023, Lonza:293, Pharmacodb:SUP-T1_1522_2019, PRIDE:PXD030304, Progenetix:CVCL_1714, PubChem_Cell_line:CVCL_1714, Wikidata:Q54970880

ID: CVCL_1714

Record Creation Time: 20220427T221613+0000

Record Last Update: 20260904T015747+0000

Ratings and Alerts

No rating or validation information has been found for SUP-T1.

No alerts have been found for SUP-T1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 547 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Garcia-Moreno M, et al. (2026) Incorporation of genome-bound cellular proteins into HIV-1 particles regulates viral infection. Cell reports, 45(4), 117090.

Jahnz H, et al. (2026) Development of a recombinant adeno-associated virus vector for human T lymphocyte- and natural killer cell-targeted gene therapy. bioRxiv : the preprint server for biology.

Songprakhon P, et al. (2026) CD138-targeted bispecific protein engager-armed T cells exhibit potent and selective cytotoxicity against multiple myeloma cells. International

immunopharmacology, 174, 116295.

Cheng J, et al. (2026) Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed/refractory CD5+ hematological malignancies. *Cell reports. Medicine*, 7(2), 102584.

Tiwarly K, et al. (2026) A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma. *Scientific reports*, 16(1).

Teran Pumar OY, et al. (2026) Pharmacologic DPP-4 inhibition promotes CD8+ T cell metabolic fitness to enhance anti-tumor activity. *bioRxiv : the preprint server for biology*.

Yang C, et al. (2025) A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity. *Cell reports. Medicine*, 6(10), 102409.

Chen SM, et al. (2025) SLFN14 functions as a P-TEFb inhibitor to modulate the transcription of HIV-1 and cellular genes. *Science advances*, 11(51), eadt7982.

Abdalla AL, et al. (2025) Lithium attenuates HIV-1 latency reversal in an autophagy-independent way. *iScience*, 28(12), 114085.

Plowman T, et al. (2025) Primate retroelement exonization and sexually dimorphic IL13RA1 transcription tune type 2 immune responses. *Science immunology*, 10(109), eadr1105.

Rujirachaivej P, et al. (2025) Engineered T cells secreting ?B7-H3-?CD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach. *Journal of translational medicine*, 23(1), 54.

Umotoy JC, et al. (2024) Inhibition of HIV-1 replication by nanobodies targeting tetraspanin CD9. *iScience*, 27(10), 110958.

Ward GA, et al. (2024) Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. *Cancer research communications*, 4(6), 1441.

Rivera M, et al. (2024) Malignant A-to-I RNA editing by ADAR1 drives T cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensing. *Cell reports*, 43(2), 113704.

Hagel KR, et al. (2023) Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. *Cancer research*, 83(4), 613.

Vamva E, et al. (2023) A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin. *Molecular therapy. Methods & clinical development*, 28, 366.

McKenzie C, et al. (2023) Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy. *Molecular therapy. Nucleic acids*, 32, 603.

Tona RM, et al. (2023) Process intensification for lentiviral vector manufacturing using tangential flow depth filtration. *Molecular therapy. Methods & clinical development*, 29, 93.

Michels KR, et al. (2023) Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. *Journal for immunotherapy of cancer*, 11(3).

Manai F, et al. (2023) Gluten Exorphins Promote Cell Proliferation through the Activation of Mitogenic and Pro-Survival Pathways. *International journal of molecular sciences*, 24(4).